Small-Molecule GLP-1 Drugs Target the Brains Emotion and Reward Centers Peptide GLP-1 agonists are difficult to manufacture, store, and administerthey must be injected
Advocacy groups and medical organizations are pushing for changes that would reclassify obesity as a chronic disease, mandating broader coverage
The GIP receptor component is hypothesised to enhance insulin sensitivity and contribute further to appetite regulation, based on preclinical and early clinical data
But I want to know from your perspective and all the research youve done around diet and dietary guidelines, what do you tell patients and what do you recommend that doctors tell their patients
Besides these side effects, you should be mindful of two other primary medical conditions
In the as-treated analysis median follow-up was 1 year [0-2] for GLP-1 RA users and 1 year [13] for users of DPP-4 inhibitors